Tuk Bert, Jousma Harmen, Gaillard Pieter J
Ry Pharma, Hofstraat 1, Willemstad, 4797 AC, Netherlands.
2-BBB Medicines, J.H. Oortweg 19, Leiden, 2333 CH, Netherlands.
F1000Res. 2017 Apr 3;6:410. doi: 10.12688/f1000research.10534.1. eCollection 2017.
Three male Caucasian patients with ALS were admitted to the hospital due to progressive dysphagia and dysarthria. During two 21-day courses of penicillin G and hydrocortisone, these patients' dysphagia and dysarthria resolved. The patient's other ALS-associated symptoms also improved, including respiratory function, coordination, walking, and muscle strength. This is the first report of a treatment with a protocol for treating dysphagia, dysarthria, respiratory depression and other ALS-related symptoms. Furthermore, the observations are consistent with the recent hypothesis that the successful treatment of ALS symptoms with this treatment course in six patients with syphilitic ALS was not directly due to the treatment of syphilis; but that the administered penicillin G and/or hydrocortisone treated these patients' ALS symptoms due the off-target pharmacological activity of penicillin G and/or hydrocortisone. This report therefore underscores the need to evaluate the efficacy of this treatment course in a clinical trial.
三名患有肌萎缩侧索硬化症(ALS)的白人男性患者因进行性吞咽困难和构音障碍入院。在接受两个为期21天的青霉素G和氢化可的松疗程后,这些患者的吞咽困难和构音障碍得到缓解。患者的其他与ALS相关的症状也有所改善,包括呼吸功能、协调性、行走能力和肌肉力量。这是首次报告采用一种治疗方案治疗吞咽困难、构音障碍、呼吸抑制及其他与ALS相关症状。此外,这些观察结果与最近的假说一致,即该治疗方案成功治疗六例梅毒性ALS患者的ALS症状并非直接归因于梅毒的治疗;而是所给予的青霉素G和/或氢化可的松因其脱靶药理活性治疗了这些患者的ALS症状。因此,本报告强调有必要在临床试验中评估该治疗方案的疗效。